logo
Plus   Neg
Share
Email

Genentech: Phase III PEMPHIX Study With Rituxan Meets Primary End Point

Genentech, affiliated to Swiss drug major Roche Group (RHHBY), announced Thursday that the Phase III PEMPHIX Study with Rituxan (Rituximab) in patients with Pemphigus Vulgaris or PV met the primary and secondary endpoints.

The study evaluated the efficacy and safety of Rituxan compared to mycophenolate mofetil or MMF that is accepted as standard of care.

Rituxan demonstrated that it is superior to standard of care in achieving sustained remission in adults with moderate to severe PV.

Genentech will present the complete data from the PEMPHIX study at an upcoming medical congress. The results will be submited to health authorities around the world, including the U.S. Food and Drug Administration.

In June 2018, Rituxan became the first and only biologic therapy approved by the FDA for the treatment of PV based on results from the Ritux 3 clinical trial. The latest PEMPHIX trial provided additional clinical evidence on the effectiveness of Rituxan for PV.

PV is a rare, serious and potentially life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has delayed the worldwide launch of its Surface Earbuds till Spring 2020. The $249 wireless earbuds were originally expected to launch this year. The delay is a setback in Microsoft's attempt to compete with Apple's latest earbuds, AirPods Pro, which has a new design and features active noise cancellation. General Motors Co. (GM) is hiring for new workforce, after cutting about some 4,000 salaried employees early this year. According to Detroit Free Press, the auto giant is hiring for a new workforce as the company invests more money to develop electric and self-driving vehicles. Earlier this year,... Australia's Federal Court has ruled in favor of more than 1,000 women in a landmark class-action lawsuit against Johnson & Johnson after they suffered severe pain and complications from the healthcare giant's pelvic mesh implants. Johnson & Johnson and its subsidiary Ethicon were accused of hiding the risks of its pelvic mesh products.
Follow RTT
>